Eli Lilly & Co.’s weight-loss and diabetes drug Mounjaro won’t be reclassified as a sleep apnea treatment in Europe, with ...

The European Medicines Agency has allowed Eli Lilly to update the product label of its weight-loss drug Mounjaro to show it ...

Eli Lilly, the pharma giant behind the popular weight-loss drug Zepbound, said it plans to test obesity medications as a ...

Eli Lilly (NYSE: LLY) has received a positive recommendation for approval from European regulators for its drug Omvoh in the ...

Stock Editorial via Getty Images An expert panel of the EU drug regulator, the European Medicines Agency (EMA), has ...

Eli Lilly (NYSE: LLY) may seem like an expensive stock to invest in right now. Its $720 billion market capitalization also ...

Eli Lilly (LLY 0.86%) and Novo Nordisk (NVO -1.53%) have competed for decades. They're both leaders in the areas of insulin ...

Eli Lilly CEO David Ricks on Tuesday said at the Economic Club of Washington that tax and regulation reform and drug ...

Eli Lilly (LLY) has added a new telehealth partner to expand access to single-dose vials of its blockbuster weight loss drug ...

Over 18 months, people taking Zepbound lost more weight on average than those on Wegovy, according to the first head-to-head ...

We recently compiled a list of the 16 Best Income Stocks To Buy According to Analysts. In this article, we are going to take ...

Eli Lilly just shared some new information. That data suggests it has an advantage against Novo Nordisk in a key market.